Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

HIKAL. vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 HIKAL.   ACTAVIS
EQUITY SHARE DATA
    HIKAL.
Mar-23
ACTAVIS
Dec-18
HIKAL./
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs45616,126-   
Low Rs21610,818-   
Sales per share (Unadj.) Rs164.13,955.8-  
Earnings per share (Unadj.) Rs6.4-1,274.2-  
Cash flow per share (Unadj.) Rs15.2416.9-  
Dividends per share (Unadj.) Rs1.200-  
Avg Dividend yield %0.40-  
Book value per share (Unadj.) Rs91.916,315.7-  
Shares outstanding (eoy) m123.30332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.03.4 60.1%   
Avg P/E ratio x52.8-10.6 -499.8%  
P/CF ratio (eoy) x22.132.3 68.4%  
Price / Book Value ratio x3.70.8 442.6%  
Dividend payout %18.90-   
Avg Mkt Cap Rs m41,4204,480,758 0.9%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m2,2240-   
Avg. sales/employee Rs Th077,851.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,076.0-  
INCOME DATA
Net Sales Rs m20,2301,315,689 1.5%  
Other income Rs m5425,160 0.2%   
Total revenues Rs m20,2841,340,849 1.5%   
Gross profit Rs m2,57134,478 7.5%  
Depreciation Rs m1,090562,428 0.2%   
Interest Rs m48175,923 0.6%   
Profit before tax Rs m1,054-578,713 -0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,595 0.0%   
Tax Rs m270-7,334 -3.7%   
Profit after tax Rs m784-423,784 -0.2%  
Gross profit margin %12.72.6 484.9%  
Effective tax rate %25.61.3 2,020.8%   
Net profit margin %3.9-32.2 -12.0%  
BALANCE SHEET DATA
Current assets Rs m9,683539,627 1.8%   
Current liabilities Rs m6,908477,372 1.4%   
Net working cap to sales %13.74.7 289.9%  
Current ratio x1.41.1 124.0%  
Inventory Days Days2620 130.8%  
Debtors Days Days8066 120.2%  
Net fixed assets Rs m15,024148,929 10.1%   
Share capital Rs m2470-   
"Free" reserves Rs m11,0880-   
Net worth Rs m11,3355,426,601 0.2%   
Long term debt Rs m4,8991,910,903 0.3%   
Total assets Rs m24,7078,483,012 0.3%  
Interest coverage x3.2-6.6 -48.2%   
Debt to equity ratio x0.40.4 122.7%  
Sales to assets ratio x0.80.2 527.9%   
Return on assets %5.1-4.1 -124.8%  
Return on equity %6.9-7.8 -88.6%  
Return on capital %9.5-4.8 -195.3%  
Exports to sales %67.60-   
Imports to sales %25.60-   
Net fx Rs m8,5000-   
CASH FLOW
From Operations Rs m3,153470,046 0.7%  
From Investments Rs m-2,923258,229 -1.1%  
From Financial Activity Rs m-77-806,740 0.0%  
Net Cashflow Rs m153-78,073 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare HIKAL. With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare HIKAL. With: HINDUSTAN BIOSCIE  CHANDRA BHAGAT PHARMA  ADVANCED ENZYME TECHNOLOGIES  ELDER PHARMA  TWILIGHT LITAKA PH.  



Today's Market

Sensex Today Trades Flat | Nifty Below 22,350 | Kotak Mahindra Bank Tanks 9% Sensex Today Trades Flat | Nifty Below 22,350 | Kotak Mahindra Bank Tanks 9%(10:30 am)

Asian stocks fell on Thursday as disappointing earnings forecasts from Facebook parent Meta Platforms hammered tech shares, while the yen's slump past 155 per dollar.